Protocols›Metabolic, weight & GH›Sleep & Recovery Starter
← Protocols
US-clinic · off-labelCommunity · convergenceNo approved clinical use

Sleep & Recovery Starter

Stack: Ipamorelin · fasted
"A single GH-secretagogue run for sleep and recovery. It reliably nudges GH/IGF-1; the sleep and recovery benefits are mostly anecdotal."
GoalSleep depth / recovery
Compounds1 · Ipamorelin
Humans exposed (est.)Moderate — undocumented
StatusMHRA (UK): not a licensed medicine — research material · FDA (US): not approved · GH-secretagogue, outcome data thin
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
US-clinic
Where / who
Community / athlete and clinic use as tagged above.
Use status
A common low-complexity GH-axis entry.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
Ipamorelin: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing; removed from Category 2 Apr 2026, 503A Bulks List decision pending the PCAC meeting 23–24 Jul 2026.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Raises GH/IGF-1; downstream outcomes thin.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Why this combination

Ipamorelin is a selective ghrelin-receptor agonist — it produces a clean pulsatile GH release. That the GH rises is real; that it improves sleep or recovery meaningfully is largely anecdotal.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Moderate

A common low-complexity GH-axis entry.

Human efficacy Weak

Raises GH/IGF-1; downstream outcomes thin.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Mechanism is real; the claimed benefits outrun the evidence.

Fast facts
Compounds

Ipamorelin

Humans exposed (est.)

Moderate — undocumented.

UK strip

GREEN — research material